Product Description
It is for slowing or reversing atrophy in dry AMD. ASP7317 is a specially created type of cells derived from human stem cells.
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Geographic Atrophy|Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
7317-CL-0003 | P1 |
Recruiting |
Macular Degeneration|Geographic Atrophy |
2026-01-31 |